Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05047601 · ClinicalTrials.gov registry record · Phase 2
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 2,954
- Enrollment target
NCT05047601: Completed Phase 2 study, sponsored by Pfizer.
NCT05047601 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 2,954 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (2121% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05047601, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 2,954 participants
- Enrollment target
Study Summary
The purpose of this clinical trial is to learn whether the study medicine prevent symptoms of COVID-19 in adults who have been exposed to household member(s) with a confirmed symptomatic COVID-19 infection. All participants in the study will receive treatment for COVID-19 as needed, based on their regular doctor's recommendation. Two-thirds of participants will also receive two study medicines (PF-07321332 and ritonavir) by mouth twice a day for either five or ten days. We will compare the experiences of people receiving the study medicines to those of the people who do not. This will help us determine if the study medicines are safe and effective
Primary Outcome
Percentage of participants who developed symptomatic Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) or Rapid Antigen Test (RAT) confirmed SARS-Cov-2 infection were reported in this outcome measure. Index case was defined as participants with symptomatic COVID-19.
Interventions
- DRUG Ritonavir
- DRUG PF-07321332
- DRUG Placebo for PF-07321332
- DRUG Placebo for Ritonavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,954 participants |
| Start Date | 2021-09-09 |
| Est. Completion | 2022-04-12 |
| Phase | Phase 2 |
What the finished NCT05047601 record still lists
NCT05047601 is an interventional study that assigns participants to a tested intervention. Its 2,954 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (2121% higher).
The record links to 0 conditions, and to 4 interventions - of which Ritonavir is the first listed.
NCT05047601 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05047601 about?
NCT05047601 is a clinical study titled "A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection". The purpose of this clinical trial is to learn whether the study medicine prevent symptoms of COVID-19 in adults who have been exposed to household member(s) with a confirmed symptomatic COVID-19 infection. All participants in the study will receive treatment for COVID-19 as needed, based on their ...
What is the current status of trial NCT05047601?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 2,954 participants. The study started on 2021-09-09. Estimated completion is 2022-04-12.
What interventions are being tested in trial NCT05047601?
The interventions under investigation include: Ritonavir (DRUG), PF-07321332 (DRUG), Placebo for PF-07321332 (DRUG), Placebo for Ritonavir (DRUG).
Who is sponsoring clinical trial NCT05047601?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05047601's enrollment target sits among peer trials
2,954 6th of 2000 higher than 1,995 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03331380 · 2,950 participants · NA
Technical Development of Cardiovascular Magnetic Resonance Imaging (CMR) Using a Low Specific Absorption Rate (SAR) Scanner System
- NCT05849961 · 2,946 participants
Exactech Hip Systems Post-Market Clinical Follow-up (PMCF)
- NCT05297734 · 2,996 participants · NA
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
- NCT03860883 · 2,998 participants · NA
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI